Taken together, the emerging clinical efficacy of Hsp90 inhibitors in related dermatoses, coupled with robust preclinical support in AD and AIBD models, strongly supports the initiation of early-phase clinical trials in patients with AD. This evidence concerns the gene HSP90AB1 and Alzheimer disease.